[Tocolysis with calcium-channel blockers and intraventricular hemorrhage].
OBJECTIVE
To determine the possible association between intraventricular hemorrhage (IVH) in very premature infants and calcium-channel blockers used as tocolytics.


METHODS
We performed a case-control study (from October 1999 to December 2002) including 51 premature infants under 30 weeks with IVH (all grade) and 112 premature infants under 30 weeks without IVH. In this study only premature infants issued from spontaneous prematurity were included. The exposure frequency to calcium-channel blockers and to other tocolytics were compared between the two groups by univariate analysis and by logistic regression analysis.


RESULTS
Calcium-channel blockers were used in monotherapy before birth in 16% of infants without IVH and in 20% of infants with IVH (P=0.55). An exposure to a bitherapy or a tritherapy with a calcium-channel blocker and one or several other tocolytics has been found in 43% of infants with IVH and in 26% of infants without IVH (P<0.05). However this association disappears after adjustment for gestational age.


CONCLUSIONS
We did not find a significant association between calcium-channel blockers used as tocolytics and an increased risk of intraventricular hemorrhage in premature infants less than 30 weeks.
Nguon
B
B
Hôpital Antoine-Béclère, 157, Rue de la Porte-de-Trivaux, Clamart Cedex, France. benedicte.nguon@voila.fr
Zupan-Simunek
V
V
Audibert
F
F
Preaux
N
N
D000328:Adult; D000704:Analysis of Variance; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D002543:Cerebral Hemorrhage / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology / Q000209:etiology*; D016015:Logistic Models; D008297:Male; D011247:Pregnancy; D012307:Risk Factors; D015145:Tocolysis / Q000009:adverse effects; D015149:Tocolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D015149:Tocolytic Agents; D014665:Vasodilator Agents